Zacks Investment Research
26 May 2026, 13:51 UTC · 23w ago
Verdict
Source says Buy. We score JNJ +0.60 across four claims.
Score confirms the headline.
Buy
Rating stated in the headline
+0.60strongly bullish
What the story claims
4 claims · scored −1 bearish … +1 bullish
The drug and biotech sector is showing signs of recovery in 2026 due to strong quarterly performances and increased M&A activity.
More positive than 75% of claims this week
Large pharmaceutical companies like Eli Lilly, Johnson & Johnson, Novo Nordisk, and Bayer are identified as attractive long-term holdings.
Continue reading
5 related stories
More positive than 71% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 61% of claims this week
The sector faces headwinds from slower-than-expected therapy launches, looming patent expirations, and pricing uncertainty.
More negative than 79% of claims this week
Competitive pressure is intensifying specifically in the obesity and cancer treatment markets.
So whatHigh competition in high-growth segments can compress margins and erode market share for individual players.
More negative than 72% of claims this week
Which stocks this story touches
More positive than 71% of ticker scores this week
The author explicitly recommends retaining the stock in one's portfolio due to the constructive outlook for large pharma.
More positive than 71% of ticker scores this week
The author explicitly recommends retaining the stock in one's portfolio due to the constructive outlook for large pharma.
More positive than 71% of ticker scores this week
The author explicitly recommends retaining the stock in one's portfolio due to the constructive outlook for large pharma.
More positive than 71% of ticker scores this week
The author explicitly recommends retaining the stock in one's portfolio due to the constructive outlook for large pharma.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
8h ago
Zacks Investment Research
30m ago
More positive than 37% of relationship scores this week
[mutual] Both are listed as key large pharmaceutical companies operating in the same competitive industry outlook.
More positive than 37% of relationship scores this week
[mutual] Both are listed as key large pharmaceutical companies operating in the same competitive industry outlook.
More positive than 37% of relationship scores this week
[mutual] Both are listed as key large pharmaceutical companies operating in the same competitive industry outlook.
More positive than 37% of relationship scores this week
[mutual] Both are listed as key large pharmaceutical companies operating in the same competitive industry outlook.
More positive than 37% of relationship scores this week
[mutual] Both are listed as key large pharmaceutical companies operating in the same competitive industry outlook.
+17.9%
Price agrees with the score
$276.32 vs $234.34 close before publication (May 22) · not market-adjusted
JNJ chart →
